Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.

A G Clark1, M Holodniy, D H Schwartz

  • 1AIDS Clinical Trial Unit, Stanford University, California.

Journal of Acquired Immune Deficiency Syndromes
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlated Gene Copy Number Changes in a Seminal Fluid Protein Network in <i>Drosophila</i>.

bioRxiv : the preprint server for biology·2025
Same author

The influence of open-top chambers on the growth and development of field bean.

The New phytologist·2021
Same author

Sex-ratio meiotic drive and interspecific competition.

Journal of evolutionary biology·2014
Same author

Using next-generation RNA sequencing to identify imprinted genes.

Heredity·2014
Same author

Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Journal of viral hepatitis·2014
Same author

Non-conflict theories for the evolution of genomic imprinting.

Heredity·2014

Combination therapy with zidovudine (ZDV) and interleukin-2 (IL-2) significantly reduced human immunodeficiency virus (HIV) proviral DNA in patients. HIV proviral DNA levels remained low during treatment and after discontinuation, indicating sustained antiviral activity.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Human immunodeficiency virus (HIV) persists as a chronic infection, necessitating effective antiviral strategies.
  • Monitoring HIV proviral DNA in peripheral blood mononuclear cells (PBMC) offers a direct measure of viral load and treatment efficacy.

Purpose of the Study:

  • To quantify changes in HIV proviral DNA levels in asymptomatic individuals receiving combination therapy.
  • To assess the antiviral activity of zidovudine (ZDV) and human recombinant interleukin-2 (rIL-2) in HIV-infected patients.

Main Methods:

  • Polymerase chain reaction (PCR) amplification was used to quantify HIV proviral DNA in PBMC from 13 HIV-seropositive individuals over 10-24 months.
  • Subjects received varying courses of ZDV and rIL-2, with periods of monotherapy and drug-free washout observed.

Related Experiment Videos

Main Results:

  • In untreated individuals, HIV provirus levels remained stable.
  • Combination therapy with ZDV and rIL-2 led to a significant decline in HIV proviral DNA (p<0.01 at week 20, p<0.04 at 12 months).
  • Proviral DNA levels remained depressed during treatment, washout periods, and showed a delayed return after therapy cessation.

Conclusions:

  • Quantification of HIV proviral DNA serves as a direct marker for assessing antiviral efficacy.
  • Combination therapy with ZDV and rIL-2 demonstrates significant and sustained antiviral activity against HIV.
  • The study highlights the potential of monitoring proviral DNA for evaluating novel therapeutic interventions.